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Abstract
Background: HERG potassium channel blockade is the major cause for drug-induced long QT syndrome,
which sometimes cause cardiac disrhythmias and sudden death. There is a strong interest in the
pharmaceutical industry to develop high quality medium to high-throughput assays for detecting
compounds with potential cardiac liability at the earliest stages of drug development. Cultivation of cells
at lower temperature has been used to improve the folding and membrane localization of trafficking
defective hERG mutant proteins. The objective of this study was to investigate the effect of lower
temperature maintenance on wild type hERG expression and assay performance.
Results: Wild type hERG was stably expressed in CHO-K1 cells, with the majority of channel protein
being located in the cytoplasm, but relatively little on the cell surface. Expression at both locations was
increased several-fold by cultivation at lower growth temperatures. Intracellular hERG protein levels were
highest at 27°C and this correlated with maximal 3H-dofetilide binding activity. In contrast, the expression
of functionally active cell surface-associated hERG measured by patch clamp electrophysiology was optimal
at 30°C. The majority of the cytoplasmic hERG protein was associated with the membranes of cytoplasmic
vesicles, which markedly increased in quantity and size at lower temperatures or in the presence of the
Ca2+-ATPase inhibitor, thapsigargin. Incubation with the endocytic trafficking blocker, nocodazole, led to
an increase in hERG activity at 37°C, but not at 30°C.
Conclusion:  Our results are consistent with the concept that maintenance of cells at reduced
temperature can be used to boost the functional expression of difficult-to-express membrane proteins and
improve the quality of assays for medium to high-throughput compound screening. In addition, these
results shed some light on the trafficking of hERG protein under these growth conditions.
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Background
Human ether-a-go-go related gene (hERG, KCNH2)
potassium channels mediate the rapid activating delayed
rectifier potassium current (IKr) in ventricular myocytes.
Loss of function mutations in hERG or the administration
of channel blockers cause a delay in membrane potential
repolarization of the cardiac action potential, and give rise
to a prolongation of the QT interval on the electrocardio-
graph ([1], for review). This 'long QT syndrome' can trig-
ger polymorphic ventricular dysrhythmias (torsades de
pointes), syncope and sudden death.
The hERG channel is blocked by a plethora of structurally
diverse compounds, including many marketed drugs,
some of which, such as terfenadine and cisapride, have
been withdrawn from the market due to this unwanted
activity [1-3]. For this reason there is strong interest within
the pharmaceutical industry in optimizing the recom-
binant expression of hERG, in order to improve the qual-
ity of medium to high-throughput assays for detecting
compounds with potential cardiac liability at the earliest
stages of drug development.
Among some 200 hereditary mutations in KCNH2 that
cause type 2 long QT (LQT2) [4], about 67% are missense
alterations, the majority of which cause trafficking defects;
that is, an overall reduction of cell surface hERG protein
[5]. In most cases, when these mutants are expressed in
HEK293 cells, the trafficking defects can be 'rescued' or at
least partially corrected by incubating cells at 27°C or by
adding hERG blockers such as E4041, or the Ca2+-ATPase
inhibitor thapsigargin [5-11]. Low temperature mainte-
nance has also been reported to increase the surface
expression of trafficking defective mutants of CFTR [12] in
stably transfected polarized CFBE41o-cells, wild type α7-
nicotinic acetylcholine receptor in SH-EP1 cells [13], as
well as the production of a number of recombinant pro-
teins that are soluble and secreted in CHO cells [14].
However, the mechanism of these temperature effects is
not well understood.
Here we report an increase in expression of wild type
hERG at lower growth temperatures and the characteriza-
tion of the accumulation of hERG protein in intracellular
vesicles in CHO-K1 cells. Our results demonstrate that
low temperature growth can be an important tool in the
development of robust drug screening assays for difficult-
to-express ion channels such as hERG.
Results
Increase in intracellular and cell surface hERG protein 
expression levels when cells were maintained at 30°C
A number of CHO-K1 stable cell lines over-expressing
wild type hERG were established. Immunocytochemistry
and confocal microscopy showed that most of the
expressed hERG protein was located intracellularly and
very little was associated with the cell surface (Fig. 1A–B).
As low temperature cultivation has been reported to
increase the surface expression of some membrane pro-
teins, as well as the production of some non-membrane
associated proteins [14,5,13], we looked at the effect of
this treatment on wild type hERG expression.
CHO hERG cells were normally maintained in culture at
37°C. Three days after switching to 30°C, hERG channel
activity was measured by planar patch clamp electrophys-
iology using an IonWorksHT automated system. Current
amplitudes measured at the tail end of a -30 mV inactiva-
tion step (see Fig. 2A, for voltage command protocol),
Subcellular localization of expressed hERG Figure 1
Subcellular localization of expressed hERG. Representative 
confocal microscopy images of cells fixed, permeablised and 
immunolabelled with anti-hERG antibody C20. CHO and 
CHO hERG cells grown at 37°C were split and kept subcon-
fluent for 3 d at 37 (A,B), 30 (C), or 27°C (D). Additional 
samples were kept at 30°C for 1 d, followed by 24 h incuba-
tion at the same temperature with 1 µM thapsigargin (E). Bar, 
5 µm.
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were 3-fold higher following incubation at 30°C with a
mean of 0.93 nA (n = 686), compared to 0.28 nA (n = 657,
p < 0.0001) from the 37°C cells (Fig. 2B–D). The propor-
tion of cells expressing tail currents above a threshold
level of 0.1 nA (sufficient, for example, for high through-
put compound screening) was also notably higher (96%
vs 75%). These results suggest there is a general increase in
expression of functional hERG protein on the cell surface
of all cells examined at the lower temperature. An eleva-
tion of total channel protein associated with the cell mem-
brane was observed at 30°C, as detected by Western blot
(data not shown). Analysis by confocal microscopy con-
firmed these findings and also showed that, both at 37
and 30°C, hERG was largely concentrated in punctate
cytoplasmic structures which became much more promi-
nent at lower temperature (Fig. 1C, D).
Similar increased expression was observed with HEK293
cells expressing recombinant hERG (data not shown), as
well as with other ion channel proteins, such as the nico-
tinic receptor subunits α4 and β2 (data not shown).
Quantification of changes in intracellular and surface 
hERG protein expression by flow cytometry
Following the initial observations described above, flow
cytometry was employed to quantify the increase in hERG
expression occurring at lower temperatures. In the first
experiment, total cellular hERG protein was measured
using fixed and permeabilized cells labelled with an anti-
body (C20) raised against a peptide sequence located at
the C-terminus of the protein which is predicted to be on
the intracellular side of the plasma-membrane (or on the
surface of internal membrane-bound organelles). Mainte-
nance of the cells at 34, 32, 30, 27 and 23°C for 3 d
increased total cellular hERG immunofluorescence com-
pared with 37°C by some 2-, 3-, 4-, 6- and 3-fold, respec-
tively. Thus, the total hERG protein expression peaked at
27°C, and then tailed off when the temperature was
reduced further to 23°C (Fig. 3A, B). Extending the
growth period from 3 to 7 d increased the expression still
further, giving levels of ~6- and 10-fold higher than 37°C,
at 30 and 27°C, respectively (data not shown), suggesting
the effect was cumulative over time. Since nearly all of the
immuno-fluorescence was cytoplasmic, these measure-
ments largely reflect the amount of intracellular located
hERG protein.
In a separate experiment, cell surface hERG was quantified
by flow cytometry using cells that were not fixed or perme-
ablized, and labelled with an antibody (2110) raised
against a peptide between TM1 and TM2, which is pre-
dicted to be located on the surface of the plasma mem-
brane. Following 3 d incubation, the increase in hERG
fluorescence was ~3.5-fold at 30°C, and 2-fold at 27°C
(Fig. 3C). These results suggest that the amplitude of
increase of hERG on the cell surface was similar to that in
the cytoplasm at 30°C, while at 27°C, a higher propor-
tion of the protein remained intracellular.
Increased functional expression of hERG at 30°C Figure 2
Increased functional expression of hERG at 30°C. HERG-
expressing CHO cells were grown at 37°C (Materials and 
Methods), and then split and kept subconfluent at either 37 
or 30°C for 3 d. Voltage command protocol (A). HERG cur-
rents were averaged from the last 200 mS of the -30 mV 
inactivation step before compound addition, subtracting the 
same recording after the application of 10 µM dofetilide. 
Patch clamp recordings made with an IonWorksHT instru-
ment from a representative cell maintained at either 37 or 
30°C (B,C, respectively). The black traces are recordings 
before compound addition. The grey traces are recordings 
following 10 µM dofetilide addition. It is noticeable that the 
difference at the initial phase of the -30 mV step was even 
bigger between the two temperatures. Population analysis of 
the hERG currents using three 384 well patch plates each (ie. 
>1000 recordings) for cells grown at 37 (open bars) and 
30°C (black bars; D).
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HERG electrophysiological activity was highest at 30°C, 
but 3H-dofetilide binding activity was optimal at 27°C
The flow cytometry experiments described above showed
that the optimal cultivation temperatures for intracellular
and surface hERG protein expression were different. We
next compared the level of functional activity expressed at
30 and 27°C, using two types of assay, patch clamp elec-
trophysiology and 3H-dofetilide binding. As before, the
patch clamp experiments were carried out by automated
planar array electrophysiology using an IonworksHT
instrument which allows larger cell samples to be exam-
ined, thereby enabling greater statistical precision. In
addition, unlike manual patch clamp, cells are sampled
randomly from the total population, giving functional
data that is more comparable to the protein expression
data obtained by flow cytometry.
HERG electrophysiological activity (Fig. 2A) was elevated
at both 30 and 27°C compared to 37°C, and was highest
at 30°C (Fig. 4A). The average currents at the tail end of
the -30 mV inactivation step from cells at 37, 30 and 27°C
were 0.38 (n = 133), 0.81 (n = 118) and 0.63 (n = 118) nA
respectively, and are statistically different from each other
(37/30°C p < 0.0001; 37/30°C p < 0.01, 30/27°C p <
0.05). On the other hand, although the level of specific
3H-dofetilide binding activity also increased at both tem-
peratures, peak levels occurred at 27°C (Fig. 4B). Thus the
ratios of total binding to non-specific binding from cells
at 37, 30 and 27°C were 1.09, 1.29 and 1.78, respectively
(37/30°C p < 0.05; 37/27°C p < 0.0001, 30/27°C p <
0.0001). Thus peak ion channel activity, which measures
functional cell surface hERG, occurred when surface-
expressed hERG protein levels were highest (Fig. 3C),
whereas maximum binding activity, which measures lig-
and binding in total crude membrane extracts composed
of both intracellular and plasmic membranes, was corre-
lated with peak expression of total hERG protein (Fig. 3A,
B). These results strongly suggest that although the bulk of
the protein is trapped inside the cell, it is nevertheless
expressed in a form capable of binding specific ligands.
The effect of lower growth temperature on hERG expres-
sion in HEK293 cells was then examined. Similar to CHO
hERG cells, growing HEK293 hERG cells at 30°C also
increased hERG current density measured by patch clamp-
ing (IonWorks, data not shown), and specific 3H-dofeti-
lide binding (Fig. 4C). The ratio of total binding to non-
specific binding from cells at 37 and 30°C were 1.13 and
1.67 respectively (p < 0.001).
Accumulation of hERG-bound intracellular vesicles at 
lower temperature
Immunocytochemistry and confocal microscopy were car-
ried out to further characterize the subcellular localization
of hERG under different conditions. At 30°C or higher,
Quantification of total and surface-associated hERG protein  in cells maintained at lower temperatures Figure 3
Quantification of total and surface-associated hERG protein 
in cells maintained at lower temperatures. Cells were cul-
tured for 3 d and analyzed by flow cytometry. Data were 
averaged from 6 samples, each of 5000 cells (un-gated), and 
normalized against CHO hERG at 37°C. Normalized fluores-
cence intensity of fixed and permeablized CHO hERG (open 
bars) and untransfected control CHO cells (filled bars) at the 
respective temperatures stained with antibody C20 (which is 
raised against a C-terminal peptide sequence; A). Represent-
ative population fluorescence plots for CHO hERG cells 
from 37, 30 and 27°C in the same experiment as A (B). Nor-
malized surface fluorescence intensity of non-fixed and non-
permeablised CHO hERG (open bars) and control cells (filled 
bars) maintained at the respective temperatures stained with 
antibody 2110 (which is raised against a peptide between 
TM1 and TM2 which is predicted to be located on the sur-
face of the plasma membrane; C).
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hERG immunofluorescence was mostly located in vesicle-
like punctate structures in the cytoplasm (Fig. 1B, C). At
27°C, in many cells, large vesicle/vacuole-like structures
appeared in which much of hERG immunofluorescence
was apparently located at their periphery (Fig. 1D). Simi-
lar hERG-loaded large/vacuole-like vesicles were rare in
30°C cells, but became abundant when combined with
the presence of the endoplasmic reticulum Ca2+-ATPase
inhibitor thapsigargin (Fig. 1E). Growth at 37°C in the
presence of the compounds also led to the appearance of
similar large/vacuole-like vesicles, albeit in a smaller pop-
ulation of cells (data not shown).
Ultrastructural studies showed a significant increase in the
number and size of vesicles in hERG transfected cells at
both 30 and 27°C (Fig. 5A, C), compared with untrans-
fected cells (Fig. 5B, D). High resolution immunogold
labelling showed that hERG was specifically associated
with the surface membrane of these structures (Fig. 5E, F).
Endocytic trafficking of membrane vesicles can be affected
by the microtubule-disrupting agent nocodazole [15-18].
As hERG is found to be accumulated in intracellular vesi-
cles, the effect of the compound on hERG expression was
investigated. Incubation of cells with 25 µM of nocoda-
zole at 37°C for 24 h led to a 60% increase in the amount
of total cellular hERG protein measured by flow cytome-
try, and a 90% increase of hERG currents determined by
patch clamping (IonWorks). Expression of hERG
increased significantly at 30°C, but did not increase fur-
ther in the presence of nocodazole (data not shown).
These results suggest that nocodazole can be a valuable
tool in boosting hERG activity at 37°C, but not at the
lower temperature.
Discussion
Stable over-expression of many recombinant membrane
associated proteins can be problematic, and overloading
the cells with such proteins can often be cytotoxic (for
review, [19]). In these cases, the protein often remains pri-
marily intracellular and can be rapidly degraded. The lack
of significant quantities on the cell surface is often a major
hindrance for drug discovery since it renders the develop-
ment of robust assays that can be used for compound
screening highly problematic. Low temperature mainte-
nance has been reported to increase the yield of some
recombinant proteins, including those that are soluble,
secreted [14], and membrane-bound [13]. In this study,
using a variety of techniques including flow cytometry,
immunoblotting and confocal and high resolution
immunocytochemistry, we have demonstrated a cumula-
tive increase over time in the level of cellular and surface
hERG protein when expressing cells are cultured at lower
temperature. These findings may be general since they
occur in cell backgrounds other than CHO, including
Comparison of hERG activity measured by patch clamp and  3H-dofetilide binding in cells maintained at different growth  temperatures Figure 4
Comparison of hERG activity measured by patch clamp and 
3H-dofetilide binding in cells maintained at different growth 
temperatures. CHO hERG cells grown at 37°C were split 
and kept subconfluent at 37, 30 or 27°C for 3 d (A,B). 
HEK293 hERG was split and kept at 37 or 30°C for 24 h (C). 
Mean tail currents recorded by patch clamping (IonWork-
sHT) from 4 independent experiments, 32–64 cells were 
patched for each data point in every experiment (A). 3H-
dofetilide binding activity for CHO hERG and HEK hERG 
membrane preps respectively (B,C). Each data point was 
from 2 independent experiments, each of 3 repeats. Back-
ground (non-specific) binding was measured in the presence 
of an excess amount of non-radioactive dofetilide. Specific 
binding (open bars) was calculated as the total counts minus 
background counts and the total: background ratio (dia-
monds) was calculated as the total counts divided by the 
background counts.
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Ultrastructural characteristics of untransfected control and hERG transfected CHO cells Figure 5
Ultrastructural characteristics of untransfected control and hERG transfected CHO cells. CHO hERG or untransfected cells 
from 37°C were split and kept subconfluent for 3 d at 30°C or 27°C. At 30°C, hERG transfected CHO cells showed numerous 
large vesicle/vacuole-like structures (A,B), which were fewer in number in untransfected 30°C CHO cells (B). At 27°C, the 
number of vesicle/vacuole-like structures were reduced compared to the 30°C cells (C,D cf/A,B). Immunolocalized hERG + 5 
and 10 nm colloidal gold secondary antibody was present on vesicle/vacuole-type membrane (E,F, respectively). hERG + 10 nm 
colloidal gold secondary labelling was present adjacent to golgi (F). cm, cell membrane; gl, golgi; nu, nucleus. Bar, A-D,5 µm. E,F, 
250 nm. E inset, 100 nm.
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HEK293, and for some other channel proteins such as nic-
otinic acetylcholine receptor subunits ([20,13] and data
not shown).
Confocal and high resolution ultrastructural immunocy-
tochemistry showed that hERG protein expression was
most prominent in intracellular vesicle/vacuole-like com-
partments. These became more abundant at 30°C and
much larger when incubated at 27°C or when treated with
the ER Ca2+-ATPase inhibitor thapsigargin. Both confocal
and electron microscopy detected hERG protein predom-
inantly on the peripheral membrane of these vesicles. It is
conceivable that such accumulation and enlargement of
the vesicle/vacuole-like structures could be the result of a
blockade en route to their destruction. Interestingly, sim-
ilar to low temperature, thapsigargin can also "rescue"
trafficking defective hERG mutants [5,6]. Our results for
the first time suggest a possible common mechanism for
these two types of treatments.
When over-expressed, some membrane proteins are read-
ily endocytosed after reaching the cell surface; some are
destined for degradation in lysosomes while others can be
recycled back to the cell surface [21-23]. The surface
expression of hERG in HEK293 cells is strictly regulated,
internalisation and lysosomal degradation can be rapidly
induced by ceramide [24]. In Swiss 3T3 cells, uptake of
exogenous materials and transport through the endocytic
pathway to lysosomes slowed at lower temperature [25].
In HeLa cells, 20°C caused a small reduction of endocyto-
sis, but a near complete block of the removal of internal-
ised dextran-containing late endosome vesicles [15]. In rat
hepatocytes, temperatures of 16–20°C blocked the transi-
tion from early to late endosomes, and from late endo-
somes to lysosomes [26,27]. Uptake and catabolism of
endocytic particles continued, but progressively slowed as
the temperature decreased from 35 to 20°C. Fusion of the
vesicles to lysosomes did not occur at 20°C or below,
while endocytosis and internal vesicle movement contin-
ued and only stopped at a much lower temperature, below
10°C [28]. Our results demonstrating the accumulation
of intracellular vesicles loaded with hERG channel protein
that is apparently fully able to bind3H-dofetilide, together
with an increased stability of the protein at the lower tem-
perature (detected by pulse chase labelling, data not
shown), are in clear agreement with these previous reports
and are consistent with a model of reduced trafficking of
vesicles further down the endocytic pathway for degrada-
tion, albeit perhaps in combination with a small, but sig-
nificant reduction in endocytosis.
The above data are further strengthened by the present
results with nocodazole. The compound has no effect on
endocytosis, but blocks microtubule-dependant steps
later in the endocytic pathway. In HeLa cells, nocodazole
prevented transferrin transport from early endosomes to
the peri-nuclear recycling compartment [15], and caused
accumulation of endosomal carrier vesicles, a compart-
ment intermediate between early and late endosomes
[16]. In a similar manner in BHK cells, nocodazole caused
the accumulation of spherical vesicles that has little fusion
activity, suggesting that transport between early and late
endosomes requires intact microtubules [17]. Further-
more, pre-treatment of CHO, 3T3, HeLa, and NRK cells
with nocodazole inhibited the content exchange of lyso-
somes in cell fusion experiments [18]. In our experiments,
the effects of nocodazole and low temperature were simi-
lar, but not additive. This is consistent with the effect of
nocodazole being due to blockade of endocytic trafficking
rather than cell cycle progression, since in the latter sce-
nario the increase in hERG expression would have been
expected to be larger when combined with 30°C. The cells
can be maintained at 30°C continuously with healthy
exponential growth, albeit at a slower rate, without any
sign of cell cycle arrest found in the cells treated with noc-
odazole, such as complete growth arrest and multi-nucle-
ation. The accumulation of hERG at 30°C was greater
than in the presence of nocodazole even at 37°C, suggest-
ing that cell cycle arrest alone can not explain this temper-
ature effect.
It is conceivable that a number of other mechanisms
could also, perhaps to a lesser extent, contribute to the
temperature effect on hERG expression, such as an
improvement in protein folding, maturation or trafficking
to the cell surface. While a number of hereditary muta-
tions in hERG render the protein misfolded and destined
for ER-associated degradation through proteosomes, there
is little evidence of this happening for the wild type pro-
tein [6,9,29,11,30].
Conclusion
Our results demonstrate that low temperature mainte-
nance can be used to boost the functional expression of
some difficult-to-express cell surface membrane associ-
ated proteins such as the hERG channel, and significantly
improve the quality of compound screening assays rang-
ing from patch clamping to radio-ligand binding. The
data also sheds some light on the mechanism of this tem-
perature effect.
We hypothesis that at the normal culturing temperature of
37°C, some of the over-expressed hERG channel protein
reaches the cell surface, but is rapidly internalized. This
and perhaps other exit trafficking routes sends the protein
to intracellular vesicles destined for degradation. Transfer
into lysosomes and, to a lesser extent, endocytosis are dis-
proportionately slowed as the temperature is reduced
leading to the accumulation of hERG-loaded vesicles as
well as an accumulation of hERG protein on the cell sur-BMC Biotechnology 2007, 7:93 http://www.biomedcentral.com/1472-6750/7/93
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face. Some of the retained hERG protein can perhaps be
trafficked back to the cell surface due to constitutive endo-
cytic recycling, similar to that occurs with some other
membrane proteins [22,31]. The aggregation of these
effects leads to an increase in protein retention both
inside the cell and on the surface membrane. It is likely
that an increase in cellular retention of trafficking defec-
tive hereditary mutant hERG proteins, through this mech-
anism, could contribute to the low temperature channel
"rescue", in addition to improvements perhaps in folding
and trafficking through the ER-Golgi network [6,9,29,11].
Methods
Materials
All cell culture reagents were obtained from Invitrogen
unless otherwise stated. Goat anti-hERG intracellular pep-
tide antibody C20 and rabbit anti-nicotinic acetylcholine
receptor α4 and β2 antibodies were obtained from Santa
Cruz. Anti-hERG extracellular peptide (AFLLKETEEGP-
PATEC) antibody 2110 was raised in rabbit and affinity
purified. Alexa488 secondary antibodies were obtained
from Cambridge Bioscience. Nocodazole was supplied by
Sigma.
Stable cell line generation and maintenance
Wild type hERG (cloned from cardiac cDNA, predicted
peptide sequence identical to Q12809 in SWISSPROT
database) stable cell line was generated in CHO-K1
(ATCC N° CRL 9618) and HEK293 cells, and nicotinic
acetylcholine receptor α4β2 stable cell line was generated
in HEK293 cells, in all cases using IRES expression con-
structs [32]. Purified plasmid DNA (1 µg) was used to
transfect ~5 × 106 cells by electroporation (standard pro-
tocol with BIORAD Gene Pulser II). After 24 h growth,
chemical selection was applied by addition of 500 µg ml-
1 geneticin for hERG, or 200 µg ml-1 hygromycin plus 500
µg ml-1  geneticin for nicotinic acetylcholine receptor
α4β2. After a further 2 wks in culture, antibiotic-resistant
clones were isolated, expanded under antibiotic selection
and subsequently stored in liquid nitrogen until subse-
quent analysis. Cells were maintained in α-MEM medium
with glutamax containing a 1% solution of non-essential
amino acids and 10% FBS for clone selection, and in
DMEM Ham's F12 medium containing glutamax and
10% FBS for the subsequent experiments, unless stated
otherwise.
Immunofluorescence confocal microscopy
Cells were fixed with Parafix (Pioneer Research Chemi-
cals), quenched in 15 mM glycine for 30 min, and perme-
abilized with 0.1% saponin in PBS plus 1% BSA. Cells
were then incubated with primary antibody, followed by
secondary antibody in permeabilization buffer, for 1 h
each, with washing between incubations. After extensive
washing over a 45 min period, cells were mounted in Cit-
ifluor (Agar Scientific) on glass slides and examined on a
Leica TCS-4D confocal microscope (Leica) using a 40×
objective oil lens.
Flow cytometry
For measuring total cellular protein, cells were removed
from adherent culture and fixed with Parafix for 10 min.
Following a PBS wash, cells were resuspended in FC buffer
(PBS plus 1 mM EDTA, 0.1% BSA, 0.5% Triton ×-100, and
0.02% sodium azide), and incubated with a mixture of 1/
500 dilution of primary and secondary antibodies for 1 h
at room temperature. Following one wash, the cells were
resuspended in PBS and analyzed on a FC500 flow cytom-
eter (Beckman Coulter). The protocol for staining non-
permeablized cells was nearly identical except that the
cells were not fixed, and Triton ×-100 was omitted from
the FC buffer.
IonWorksHT patch-clamp electrophysiology recording
Planar array patch clamp electrophysiological recordings
were carried out using a 384-well IonWorksHT reader
(Molecular Devices [33]). A fresh cell suspension in exter-
nal PBS was placed in the cell boat on the deck of the
instrument and the experiment started within 2 min. Fol-
lowing a 10 min period for the cells to seal to the sub-
strate, the amphoterocin (100 µM) containing internal
solution (140 mM KCl, 1 mM MgCl2, 1 mM EGTA, 20
mM HEPES, pH 7.3 with KOH) was introduced and left to
equilibrate for a further 4 min. During this time the perfo-
rated patch clamp configuration was achieved with esti-
mated access resistances of 5–10 MΩ. Cells were clamped
at a holding potential of -80 mV for 30s before ionic cur-
rents were measured using the following step protocol: 40
mV 500 ms, -30 mV 2000 ms before returning to -80 mV
(Fig. 2A). The same voltage step was applied after the
addition of 10 µM dofetilide. HERG currents were col-
lected at the tail end of the -30 mV inactivation step, by
averaging recordings from the last 200 ms and subtracting
the same current after compound addition. Currents
greater than 0.1 nA after subtraction were included in the
analysis, and commonly represent around 80% of all cells
recorded from. Statistics was carried out using unpaired
students t-test, and a p < 0.05.
3H-dofetilide binding assay
Cells were removed from the bottom of tissue culture ves-
sels by 5 min incubation in Versene (Invitrogen), diluted
with 10 times the amount of growth medium, and pel-
leted by centrifugation. Each 0.1 ml aliquot of the pellet
was resuspended in 1 ml of lysis buffer (50 mM HEPES,
pH 7.4, 1 mM EDTA, 1 tablet complete protease inhibitor
cocktail per 50 ml) and passed 22 times through a 25 G
fine needle with a 1 ml disposable syringe. This was fol-
lowed by centrifugation at 1,500 rpm for 10 min at 4°C
in a bench-top centrifuge to clear cell debris, and a furtherBMC Biotechnology 2007, 7:93 http://www.biomedcentral.com/1472-6750/7/93
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spin of 14,000 rpm at 4°C to pellet the membrane. The
pellet was resuspended in 200 µl of lysis buffer without
protease inhibitors, snap frozen on dry ice and stored at -
80°C.
Binding assays were performed in 384-well format using
120 µg per well wheat germ agglutinin SPA beads (Amer-
sham) pre-coated with 2 µg membrane protein, and 5
nM3H-dofetilide (Amersham), in buffer containing 25
mM HEPES, 1.2 mM MgCl2 (adjusted to pH 7.4 with KCl),
and 0.2% pluronic. Following 0.5 h incubation, plates
were read on a ViewLux instrument (Perkin Elmer 1430).
Electron microscopy
For conventional electron microscopy, cell pellets were
fixed in 3% fresh glutaraldehyde in PBS, pH 7.4, and proc-
essed using standard procedures [34]. Cells were photo-
graphed at × 2,500–60,000 in a Phillips 7100 TEM.
For high resolution immunolocalization, cell pellets were
frozen in liquid nitrogen at ~2100 bar (BAL TEC, HPM
010), freeze-substituted (Leica, AFS) at -90°C in 0.1% ura-
nyl acetate in acetone over 4 d and embedded in LR gold
polymerized under UV light at -25°C. Thin sections were
cut and placed on formvar and carbon coated nickel slot
grids and sequentially incubated in PBS containing 1%
normal donkey serum and 0.2% Tween-20 (blocking
buffer; 30 min), and antibody raised against human
HERG (1:100; Santa Cruz; sc-15968) in blocking buffer
for 18 h at 4°C, then rinsed and incubated in secondary
antibodies conjugated to 5 and 10 nm colloidal gold
(1:40; British Biocell) in 0.01% Tween-20. Sections were
subsequently treated with 1% glutaraldehyde in PBS, and
stained conventionally.
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